Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Vaccines
Investigators at University of Washington, Fred Hutchinson Cancer Research Center zero in on vaccines
October 14th, 2008
A report, 'Evaluating a surrogate endpoint at three levels, with application to vaccine development,' is newly published data in Statistics In Medicine. "Identification of an immune response to vaccination that reliably predicts protection from clinically significant infection, i.e. an immunological surrogate endpoint, is a primary goal of vaccine research. Using this problem of evaluating an immunological surrogate as an illustration, we describe a hierarchy of three criteria for a valid surrogate endpoint and statistical analysis frameworks for evaluating them," scientists writing in the journal Statistics In Medicine report. "Based on a...
Source: Cancer Weekly (2008-10-14)
|
